Committee(s):	Dated:
Health and Wellbeing Board - For Information	16092022
Subject: Pharmaceutical Needs Assessment 2022	Public
Which outcomes in the City Corporation's Corporate Plan does this proposal aim to impact directly?	2,4
Does this proposal require extra revenue and/or capital spending?	N
If so, how much?	
What is the source of Funding?	
Has this Funding Source been agreed with the Chamberlain's Department?	
Report of: Dr Sandra Husbands, Director of Public Health	For Information
Report author: Andrew Trathen, Consultant in Public Health	

### Summary

The Health and Wellbeing Board has a statutory duty to produce a Pharmaceutical Needs Assessment (PNA) every three years. The current deadline is 1<sup>st</sup> October 2022, and the PNA has now been produced and published in advance of this date.

The report has identified no gaps in pharmaceutical services for the City of London.

### Recommendation(s)

#### Members are asked to:

- Note that the PNA report has been produced and published, meeting the Health and Wellbeing Board's statutory obligation to produce the Pharmaceutical Needs Assessment by 1<sup>st</sup> October 2022.
- Note that the report has identified no gaps in pharmaceutical services for the City of London.

## **Main Report**

# **Background**

1.1 The PNA is a report of the present needs for pharmaceutical services. It is used to identify any gaps in current services or improvements that could be made in future pharmaceutical service provision. To prepare the report, data is gathered from pharmacy contractors, pharmacy users and other residents and from a range of sources (commissioners, planners and others). This includes stakeholders from neighbouring areas outside the City of London. The report also

- includes a range of maps that are produced from data collected as part of the PNA process.
- 1.2 The PNA Steering Group had its first meeting on 7<sup>th</sup> October 2021. In November 2021, the Health and Wellbeing Board formally delegated authority to the steering group to produce the final report.
- 1.3 The provider produced a full draft of the PNA in April 2022. Following this, the draft was put out for public consultation for 9 weeks between 9th May and 11th July. Comments received were then reviewed and addressed by the provider as appropriate, and included in a revised draft.
- 1.4 The steering group met for the final time in July 2022 to review and approve the revised draft, prior to Soar Beyond submitting the final version in August. The final version contains a full account of the process undertaken to produce the PNA.
- 1.5 Key findings from the City of London PNA include:
  - The City of London has 14 community pharmacies (as of January 2022) for a
    population of around 10,238, and a daytime worker population of 522,000 (prior
    to the COVID-19 pandemic). Provision of current pharmaceutical services and
    locally commissioned services are well distributed, serving all the main
    population centres. There is excellent access to a range of services
    commissioned and privately provided from pharmaceutical service providers.
  - Using current population estimates, the number of community pharmacies per 100,000 population for City of London is currently 137.0, which has decreased from 211.8 in 2018.
  - The majority (93%) of community pharmacies in the City of London are open weekday evenings (after 6 pm) and on Saturdays (36%).
  - A number are open on Sundays (21%), mainly in shopping areas. There is a much higher than national ratio of multiples to independent, providing a good choice of providers to local residents.
- 1.6 The PNA will shortly be published on the City of London website. It will be maintained with updates should circumstances change throughout the life of the document by the public health team. The next PNA will be due for publication by October 2025.

### **Proposals**

- 2.1 The board is asked to note that the PNA has now been produced and the statutory duty to publish this document by 1<sup>st</sup> October 2022 has been met (Appendix 1).
- 2.2 The board is also asked to note that the PNA has identified no gaps in pharmaceutical services for the City of London.

## **Corporate & Strategic Implications**

3.1

- Strategic implications none.
- Financial implications none
- Resource implications none
- Legal implications none
- Risk implications none
- Equalities implications An equalities impact assessment was produced by the provider, and identified no equalities impacts nor any gaps in services.
- Climate implications none
- Security implications none

### Conclusion

4.1 The City of London has met its statutory obligation to produce the PNA, which will be maintained for the three years until the next PNA is due.

# **Appendices**

• Appendix 1 – City of London Pharmaceutical Needs Assessment 2022

## **Report Author**

Andrew Trathen
Consultant in Public Health, City and Hackney

E: andrew.trathen@hackney.gov.uk